Skip to main content
Premium Trial:

Request an Annual Quote

Stelios Papadopoulos

Premium
Regulus Therapeutics, the microRNA joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week announced that it has appointed Stelios Papadopoulos to its board of directors.
 
Papadopoulos recently retired from Cowen and Company, where he served as an investment banker focused on pharmaceuticals and biotechnology, according to Regulus. Before then, he was an investment banker at PaineWebber.
 
He also held faculty positions at New York University Medical Center and continues to be an adjunct associate professor of cell biology at that institution. He holds a PhD in biophysics and an MBA in finance from New York University.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.